Notice of NIGMS Participation in PA-18-609 Development of Novel and Emerging Technologies for Cryogenic or Long-term Preservation and Revival of Drosophila and Zebrafish Genetic Stocks (R41/R42 Clinical Trial Not Allowed)

Notice Number: NOT-GM-18-019

Key Dates
Release Date: February 23, 2018

Related Announcements
PA-18-609

Issued by
National Institute of General Medical Sciences (NIGMS)

Purpose

he purpose of this Notice is to inform potential applicants that the National Institute of General Medical Sciences is participating, effective immediately, in the Funding Opportunity Announcement (FOA), PA-18-609 "Development of Novel and Emerging Technologies for Cryogenic or Long-term Preservation and Revival of Drosophila and Zebrafish Genetic Stocks (R41/R42 Clinical Trial Not Allowed)".

The following changes have been made to PA-18-609 (shown in italics) to reflect NIGMS’s participation in this FOA.

Part 1. Overview Information Components of Participating Organizations

Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs (ORIP)
National Institute of General Medical Sciences (NIGMS)

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.351; 93.859

Section VII. Agency Contacts Part 2. Full Text of Announcement

The following contacts have been added for NIGMS:


Dmitriy Krepkiy, Ph.D.
National Institute of General Medical Sciences (NIGMS)
Telephone: 301-435-0752
Email: [email protected]


Justin Rosenzweig
National Institute of General Medical Sciences (NIGMS)
Telephone: 301-594-0158
Email: [email protected]

All other aspects of this FOA remain the same.

Inquiries

Please direct all inquiries to:

Dmitriy Krepkiy, Ph.D.
National Institute of General Medical Sciences (NIGMS)
Telephone: 301-435-0752
Email: [email protected]